Crispr Therapeutics AG(CH:1CG)
CHF 39.800.00 (0.00%)
CH:1CG
Crispr Therapeutics AG stock forecast
CHF 39.80
At close:0.00 (0.00%)
Crispr Therapeutics AG (1CG) Stock Forecast & Price Target
2 Followers
1CG Analyst Ratings
Moderate Buy
8Buy5Hold0Sell
Based on 13 analysts giving stock ratings to Crispr Therapeutics AG in the past 3 months
1CG Stock 12 Month Forecast
Average Price Target
CHF59.29▲(48.99% Upside)Based on 13 Wall Street analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. The average price target is CHF 59.29 with a high forecast of CHF 90.80 and a low forecast of CHF 37.14. The average price target represents a 48.99% change from the last price of CHF 39.80.
Past 12 Months12 Month ForecastJan2026Oct2026
HighCHF90.80
AverageCHF59.29
LowCHF37.14
Highest Price TargetHighestCHF90.80Average Price TargetCHF59.29Lowest Price TargetLowestCHF37.14
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Mitchell Kapoor | H.C. Wainwright | CHF66.03 | buy | 65.93%Upside | Reiterated | 11/10/26 | ||
| Gil Blum | Needham | CHF67.68 | buy | 70.08%Upside | Reiterated | 11/10/26 | ||
| Edward Tenthoff | Piper Sandler | CHF90.80 | buy | 128.15%Upside | Reiterated | 11/09/26 | ||
| Brian Cheng | J.P. Morgan | CHF55.30 | buy | 38.96%Upside | Reiterated | 11/09/26 | ||
| Joon Lee | UBS | CHF42.92 | hold | 7.85%Upside | Reiterated | 11/09/26 | ||
| Yigal Nochomovitz | Citi | CHF74.29 | buy | 86.67%Upside | Reiterated | 11/08/26 | ||
| Yanan Zhu | Wells Fargo | CHF61.91→CHF57.78 | hold | 45.19%Upside | Assigned | 11/04/26 | ||
| Alec Stranahan | Bank of America Securities | CHF65.21→CHF66.03 | buy | 65.93%Upside | Reiterated | 11/04/26 | ||
| Luca Issi | RBC Capital | CHF41.27 | hold | 3.70%Upside | Reiterated | 11/03/26 | ||
| Tyler Van Buren | TD Cowen | CHF37.14 | hold | -6.67%Downside | Reiterated | 10/21/26 | ||
| Jonathan Miller | Evercore ISI | CHF62.73 | buy | 57.63%Upside | Reiterated | 08/31/26 | ||
| Maxwell Skor | Morgan Stanley | CHF49.53 | hold | 24.45%Upside | Reiterated | 08/28/26 | ||
| Sami Corwin | William Blair | ― | buy | ― | Reiterated | 08/28/26 | ||
| Salveen Richter | Goldman Sachs | CHF39.62→CHF45.40 | hold | 14.07%Upside | Assigned | 08/10/26 | ||
| Silvan Turkcan | Citizens JMP | CHF66.03 | buy | 65.93%Upside | Reiterated | 07/22/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Mitchell KapoorH.C. Wainwright | BuyReiteratedCHF66.03 | 11/10/26 | 65.93%Upside | ||
| Gil BlumNeedham | BuyReiteratedCHF67.68 | 11/10/26 | 70.08%Upside | ||
| Edward TenthoffPiper Sandler | BuyReiteratedCHF90.80 | 11/09/26 | 128.15%Upside | ||
| Brian ChengJ.P. Morgan | BuyReiteratedCHF55.30 | 11/09/26 | 38.96%Upside | ||
| Joon LeeUBS | HoldReiteratedCHF42.92 | 11/09/26 | 7.85%Upside | ||
| Yigal NochomovitzCiti | BuyReiteratedCHF74.29 | 11/08/26 | 86.67%Upside | ||
| Yanan ZhuWells Fargo | HoldAssignedCHF61.91→CHF57.78 | 11/04/26 | 45.19%Upside | ||
| Alec StranahanBank of America Securities | BuyReiteratedCHF65.21→CHF66.03 | 11/04/26 | 65.93%Upside | ||
| Luca IssiRBC Capital | HoldReiteratedCHF41.27 | 11/03/26 | 3.70%Upside | ||
| Tyler Van BurenTD Cowen | HoldReiteratedCHF37.14 | 10/21/26 | -6.67%Downside | ||
| Jonathan MillerEvercore ISI | BuyReiteratedCHF62.73 | 08/31/26 | 57.63%Upside | ||
| Maxwell SkorMorgan Stanley | HoldReiteratedCHF49.53 | 08/28/26 | 24.45%Upside | ||
| Sami CorwinWilliam Blair | BuyReiterated | 08/28/26 | ― | ||
| Salveen RichterGoldman Sachs | HoldAssignedCHF39.62→CHF45.40 | 08/10/26 | 14.07%Upside | ||
| Silvan TurkcanCitizens JMP | BuyReiteratedCHF66.03 | 07/22/26 | 65.93%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Crispr Therapeutics AG
3 Months
Success Rate19/36 ratings generated profit
53%
Average Return
+9.70%
Copying Geulah Livshits's trades and holding each position for 3 Months would result in 52.78% of your transactions generating a profit, with an average return of +9.70% per trade.
1 Year
Success Rate8/20 ratings generated profit
40%
Average Return
+6.44%
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +6.44% per trade.
2 Years
Success Rate9/25 ratings generated profit
36%
Average Return
-5.17%
Copying Edward Tenthoff's trades and holding each position for 2 Years would result in 36.00% of your transactions generating a profit, with an average return of -5.17% per trade.
1CG Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 8 | 7 | 10 |
| Buy | 7 | 8 | 7 | 7 | 4 |
| Hold | 6 | 8 | 7 | 9 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 22 | 25 | 22 | 23 | 21 |
In the current month, 1CG has received 14 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. 1CG average Analyst price target in the past 3 months is 59.29.
1CG Financial Forecast
HighCHF-0.62
ConsensusCHF-0.97
LowCHF-1.77
1CG Earnings Forecast
Next quarter’s earnings estimate for 1CG is -CHF 0.97 with a range of -CHF 1.77 to -CHF 0.62. The previous quarter’s EPS was -CHF 0.95. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighCHF46.7M
ConsensusCHF9.36M
LowCHF0.00
1CG Sales Forecast
Next quarter’s sales forecast for 1CG is CHF 9.36M with a range of CHF 0 to CHF 46.70M. The previous quarter’s sales results were CHF 10.46M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
1CG Stock Forecast FAQ
What is CH:1CG’s average 12-month price target, according to analysts?
Based on analyst ratings, Crispr Therapeutics AG’s 12-month average price target is CHF59.29.
What is CH:1CG’s upside potential, based on the analysts’ average price target?
Crispr Therapeutics AG has 48.99% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Crispr Therapeutics AG a Buy, Sell or Hold?
Crispr Therapeutics AG has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 5 hold ratings and 0 sell ratings.
What is Crispr Therapeutics AG’s share price target?
The average share price target for Crispr Therapeutics AG is CHF59.29. This is based on 13 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF90.80, and the lowest forecast is CHF37.14. The average share price target represents a 48.99% increase from the current price of CHF39.797.
What do analysts say about Crispr Therapeutics AG?
Crispr Therapeutics AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Street analysts.
How can I buy shares of Crispr Therapeutics AG?
To buy shares of CH:1CG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
